Literature DB >> 20955961

Cystic fibrosis-associated liver disease.

Ulrike Herrmann1, Gerd Dockter, Frank Lammert.   

Abstract

Liver disease is increasingly common in cystic fibrosis (CF). As new therapeutic options emerge, life expectancy increases and common hepatobiliary manifestations impact on quality of life and survival of CF patients. Hepatobiliary abnormalities in CF vary in nature and range from defects attributable to the underlying CFTR gene defect to those related to systemic disease and malnutrition. Today complications of liver disease represent the third most frequent cause of disease-related death in patients with CF. Here we review molecular and clinical genetics of CF, including genetic modifiers of CF-associated liver disease, and provide practical recommendations for genetic testing, diagnosis and treatment of hepatobiliary manifestations in CF.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20955961     DOI: 10.1016/j.bpg.2010.08.003

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  25 in total

Review 1.  Genome-wide association studies and genetic risk assessment of liver diseases.

Authors:  Marcin Krawczyk; Roman Müllenbach; Susanne N Weber; Vincent Zimmer; Frank Lammert
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-11-02       Impact factor: 46.802

Review 2.  Gastrointestinal Manifestations of Cystic Fibrosis.

Authors:  Thomas Kelly; James Buxbaum
Journal:  Dig Dis Sci       Date:  2015-02-04       Impact factor: 3.199

3.  Knockdown of ezrin causes intrahepatic cholestasis by the dysregulation of bile fluidity in the bile duct epithelium in mice.

Authors:  Ryo Hatano; Kaori Akiyama; Atsushi Tamura; Shigekuni Hosogi; Yoshinori Marunaka; Michael J Caplan; Yoshiyuki Ueno; Sachiko Tsukita; Shinji Asano
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

Review 4.  Lung transplantation for cystic fibrosis: results, indications, complications, and controversies.

Authors:  Joseph P Lynch; David M Sayah; John A Belperio; S Sam Weigt
Journal:  Semin Respir Crit Care Med       Date:  2015-03-31       Impact factor: 3.119

5.  CFTR dysfunction predisposes to fibrotic liver disease in a murine model.

Authors:  Camilia R Martin; Munir M Zaman; Gyanprakash A Ketwaroo; Abdul Q Bhutta; Emmanuel Coronel; Yury Popov; Detlef Schuppan; Steven D Freedman
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-06-07       Impact factor: 4.052

6.  Role of transient elastography and APRI in the assessment of pediatric cystic fibrosis liver disease.

Authors:  Jessica P Woolfson; Richard A Schreiber; Shraavan Raveendran; Mark Chilvers; Collin Barker; Orlee R Guttman
Journal:  Can Liver J       Date:  2021-02-24

Review 7.  Cirrhosis and other liver disease in cystic fibrosis.

Authors:  Thomas Flass; Michael R Narkewicz
Journal:  J Cyst Fibros       Date:  2012-12-20       Impact factor: 5.482

Review 8.  Liver disease in cystic fibrosis: an update.

Authors:  Giuseppe Fabio Parisi; Giovanna Di Dio; Chiara Franzonello; Alessia Gennaro; Novella Rotolo; Elena Lionetti; Salvatore Leonardi
Journal:  Hepat Mon       Date:  2013-08-14       Impact factor: 0.660

Review 9.  Aetiopathogenesis of liver changes in the course of cystic fibrosis, considering disturbances of the bile acid profile as well as genetic and immunological factors.

Authors:  Sabina Więcek; Halina Woś; Urszula Grzybowska-Chlebowczyk
Journal:  Prz Gastroenterol       Date:  2013-10-28

10.  Serum proteome profiling identifies novel and powerful markers of cystic fibrosis liver disease.

Authors:  Timo Rath; Lisa Hage; Marion Kügler; Katrin Menendez Menendez; Reinhart Zachoval; Lutz Naehrlich; Richard Schulz; Martin Roderfeld; Elke Roeb
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.